$JBSS

Short Interest in John B. Sanfilippo & Son, Inc. (NASDAQ:JBSS) Drops By 21.1%

Short interest for John B. Sanfilippo & Son, Inc. (NASDAQ:JBSS) decreased by 21.1% in December to 153,925 shares. Analysts currently have a "Hold" rating on the stock with a consensus price target of $109.00. The company recently reported strong quarterly earnings, beating estimates, and paid a special dividend.

Original reporting
MarketBeat · MarketBeat
Published Jan 18, 2026, 6:23 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jan 18, 2026, 6:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Short Interest in John B. Sanfilippo & Son, Inc. (NASDAQ:JBSS) Drops By 21.1% — source image
Decision brief

The 30-second read

$JBSSBullishMed
01

Why it matters

The significant decrease in short interest suggests traders are less pessimistic, possibly due to positive earnings and analyst ratings.

02

Market read

The news indicates a potentially bullish short-term outlook for JBSS, with implications for retail and food sector investors.

03

What to watch

Potential upcoming macroeconomic headwinds or sector-specific challenges that could impact stock performance despite positive short interest trends.

Timing: short-term (1-4 weeks)

Background

John B. Sanfilippo & Son, Inc. reported strong quarterly earnings and paid a special dividend, boosting investor confidence.

Company-level read

Ticker impact

$JBSSBullishMedium confidence
Context

The significant decrease in short interest (21.1%) indicates a potential shift in market sentiment and trader positioning.

Expected impact

Moderate upward price movement expected over the next 2-4 weeks.

Evidence & confidence

The decline in short interest coupled with strong quarterly earnings and a positive analyst rating indicates a bullish sentiment, though overall market conditions and industry factors should be considered.

Market effects

The retail and wholesale sector may experience positive sentiment due to improved earnings and reduced short interest in JBSS.

Limited regional impact; primarily affects investors focused on the NASDAQ and retail sector.

Minimal global market relevance; specific to sector and regional investors.

Counterpoint

The decline in short interest may be a temporary correction; underlying fundamentals or broader market downturns could negate the bullish signals.

Key entities

  • John B. Sanfilippo & Son, Inc.

    A leading producer of nut and snack products listed on NASDAQ.

Related articles

$JBSSMed

JBSS Q4 2026 Earnings Call Transcript

JBSS reported Q4 2026 net sales up 4.2% to $280.4M, but net income fell to $8.4M from $13.5M YoY. Challenges included higher costs and manufacturing inefficiencies. Priorities for 2027 include restoring snack volume, expanding the Thar portfolio, and managing cost volatility. The company expects $300M in potential new growth.

$JBSSMed

SANFILIPPO JOHN B & SON INC (JBSS): Results of Operations and Financial Condition

SANFILIPPO JOHN B & SON INC (JBSS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 John B. Sanfilippo & Son, Inc. Reports Fiscal 2026 Fourth Quarter and Full Year Results Fourth Quarter Net Sales Increased 4.2%; Sales Volume Increased 1.4% Elgin, IL, August 19, 2026 -- John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS) (the “Company”) today announced fi

$NXEMed

Is BHP Group (BHP) the Missing Piece in NexGen Energy (NXE)’s $1 Billion Financing Plan?

NexGen Energy (NXE) is in talks with BHP Group (BHP) for a potential equity stake and financing for its Rook I uranium project. NexGen aims to raise $1 billion over nine months. BHP reported strong financials, with $33 billion in EBITDA and $9.8 billion in free cash flow. NexGen has no revenue but holds $970.25 million in cash. Investors should watch for a formal partnership between the two.

$AZNMed

13 clinical candidates revealed in Chicago

At the American Chemical Society Fall 2026 meeting, 13 new drug candidates were unveiled by various companies, targeting diseases like cancer, lupus, and acne. Presenters included Quanta Therapeutics, AstraZeneca, Novartis, and Pfizer, among others, discussing their drug discovery strategies and clinical trials.